Fecal lactoferrin: A noninvasive fecal biomarker for the diagnosis and surveillance of pouchitis

Diseases of the Colon and Rectum

Volumn 56, Issue 6, 2013, Pages 733-737

  Gonsalves, S ^a   Lim, M ^a   Finan, P ^a   Sagar, P ^a   Burke, D ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Fecal biomarker; Ileal pouch anal anastomosis; Lactoferrin; Pouchitis; Ulcerative colitis

Indexed keywords

CIPROFLOXACIN; LACTOFERRIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL EVALUATION; DISEASE ACTIVITY; DISEASE SURVEILLANCE; FALSE POSITIVE RESULT; FECES LEVEL; FEMALE; HUMAN; ILEITIS; INTESTINE BIOPSY; LACTOFERRIN FECES LEVEL; LIQUID FECES; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RAPID TEST; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; FECES; FEMALE; HUMANS; IMMUNOCHROMATOGRAPHY; LACTOFERRIN; MALE; MIDDLE AGED; POUCHITIS; SENSITIVITY AND SPECIFICITY;

EID: 84879080124     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e318280194a     Document Type: Article

References (26)

1. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800-803.
2. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
3. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856-1860.
4. Abdelrazeq AS, Lund JN, Leveson SH. Implications of pouchitis on the functional results following stapled restorative proctocolectomy. Dis Colon Rectum. 2005;48:1700-1707.
5. Karlbom U, Raab Y, Ejerblad S, Graf W, Thörn M, Pâhlman L. Factors influencing the functional outcome of restorative proctocolectomy in ulcerative colitis. Br J Surg. 2000;87:1401-1408.
6. Rado TA, Bollekens J, St Laurent G, Parker L, Benz EJ Jr. Lactoferrin biosynthesis during granulocytopoiesis. Blood. 1984;64:1103-1109.
7. Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1992;30:1238-1242.
8. D'Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
9. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
10. Lim M, Gonsalves S, Thekkinkattil D, et al. The assessment of a rapid noninvasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis Colon Rectum. 2008;51:96-99.
11. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1280-1286.
12. Langhorst J, Boone J. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. Drugs Today. 2012;48:149-161.
13. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415.
14. Lim M, Sagar P, Finan P, Burke D, Schuster H. Dysbiosis and pouchitis. Br J Surg. 2006;93:1325-1334.
15. Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013-1023.
16. Navaneethan U, Shen B. Laboratory tests for patients with ileal pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am J Gastroenterol. 2009;104:2606-2615.
17. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674.
18. Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol. 1980;24:393-398.
19. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
20. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study. Scand J Gastroenterol. 1992;27:793-798.
21. Thomas P, Rihani H, Røseth A, et al. Assessment of ileal inflammation of the pouch by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214-220.
22. Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980-984.
23. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res. 2000;20(6D):4965-4968.
24. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40:1493-1494.
25. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal M2-pyruvate kinase: a novel, noninvasive marker of ileal pouch inflammation. Eur J Gastroenterol Hepatol. 2009;21:544-550.
26. Parsi MA, Ellis JJ, Lashner BA. Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol. 2008;42:799-805.